KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) EBIAT (2016 - 2025)

Pfizer (PFE) has disclosed EBIAT for 17 consecutive years, with -$1.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT fell 502.95% to -$1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $13.5 billion, a 68.07% increase, with the full-year FY2025 number at $7.8 billion, down 3.48% from a year prior.
  • EBIAT was -$1.6 billion for Q4 2025 at Pfizer, down from $9.3 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $26.4 billion in Q4 2022 to a low of -$2.4 billion in Q4 2023.
  • A 5-year average of $4.7 billion and a median of $2.9 billion in 2025 define the central range for EBIAT.
  • Biggest YoY gain for EBIAT was 6980.49% in 2025; the steepest drop was 502.95% in 2025.
  • Pfizer's EBIAT stood at $590.0 million in 2021, then crashed by 61.86% to $225.0 million in 2022, then plummeted by 73.33% to $60.0 million in 2023, then skyrocketed by 578.33% to $407.0 million in 2024, then crashed by 502.95% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's EBIAT are -$1.6 billion (Q4 2025), $9.3 billion (Q3 2025), and $2.9 billion (Q2 2025).